SE0300988D0 - New use - Google Patents

New use

Info

Publication number
SE0300988D0
SE0300988D0 SE0300988A SE0300988A SE0300988D0 SE 0300988 D0 SE0300988 D0 SE 0300988D0 SE 0300988 A SE0300988 A SE 0300988A SE 0300988 A SE0300988 A SE 0300988A SE 0300988 D0 SE0300988 D0 SE 0300988D0
Authority
SE
Sweden
Prior art keywords
new use
angiotensin
prevention
treatment
combination
Prior art date
Application number
SE0300988A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Ljunggren
Anders Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300988A priority Critical patent/SE0300988D0/xx
Publication of SE0300988D0 publication Critical patent/SE0300988D0/xx
Priority to KR1020057017718A priority patent/KR20050114671A/ko
Priority to CA002520960A priority patent/CA2520960A1/en
Priority to US10/550,760 priority patent/US20060194856A1/en
Priority to JP2006507997A priority patent/JP2006522115A/ja
Priority to EP04724927A priority patent/EP1613309A1/en
Priority to PCT/SE2004/000505 priority patent/WO2004087136A1/en
Priority to AU2004226517A priority patent/AU2004226517B2/en
Priority to NZ542640A priority patent/NZ542640A/en
Priority to BRPI0408979-0A priority patent/BRPI0408979A/pt
Priority to MXPA05010660A priority patent/MXPA05010660A/es
Priority to CNA2004800093941A priority patent/CN1771033A/zh
Priority to IL170706A priority patent/IL170706A0/en
Priority to NO20054370A priority patent/NO20054370L/no
Priority to ZA200507945A priority patent/ZA200507945B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0300988A 2003-04-03 2003-04-03 New use SE0300988D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
CNA2004800093941A CN1771033A (zh) 2003-04-03 2004-03-31 应用atii拮抗剂治疗或预防代谢综合征
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
NZ542640A NZ542640A (en) 2003-04-03 2004-03-31 Use of angiontensin II antagonists including losartan, candesartan, cilexetil, irbesartan and candesartan for the treatment or prevention of metabolic syndrome or Syndrome X
US10/550,760 US20060194856A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
JP2006507997A JP2006522115A (ja) 2003-04-03 2004-03-31 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用
EP04724927A EP1613309A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
KR1020057017718A KR20050114671A (ko) 2003-04-03 2004-03-31 대사 증후군의 치료 또는 예방을 위한 ａｔｉｉ 길항제의용도
AU2004226517A AU2004226517B2 (en) 2003-04-03 2004-03-31 Use of ATII antagonist for the treatment or prevention of metabolic syndrome
CA002520960A CA2520960A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
BRPI0408979-0A BRPI0408979A (pt) 2003-04-03 2004-03-31 uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica
MXPA05010660A MXPA05010660A (es) 2003-04-03 2004-03-31 Uso de anti-antagonistas para el tratamiento o prevencion de sindrome metabolico.
IL170706A IL170706A0 (en) 2003-04-03 2005-09-06 Use of atii antagonist for the treatment or prevention of metabolic syndrome
NO20054370A NO20054370L (no) 2003-04-03 2005-09-21 Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom
ZA200507945A ZA200507945B (en) 2003-04-03 2005-09-30 Use of ATII antagonist for the treatment or prevention of metabolic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Publications (1)

Publication Number Publication Date
SE0300988D0 true SE0300988D0 (sv) 2003-04-03

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132555A1 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20150051220A1 (en) * 2012-03-16 2015-02-19 Glucox Biotech Ab Compounds for use in therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
HUP0301335A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제

Also Published As

Publication number Publication date
EP1613309A1 (en) 2006-01-11
KR20050114671A (ko) 2005-12-06
NO20054370D0 (no) 2005-09-21
IL170706A0 (en) 2009-02-11
JP2006522115A (ja) 2006-09-28
CN1771033A (zh) 2006-05-10
BRPI0408979A (pt) 2006-04-04
NZ542640A (en) 2008-06-30
WO2004087136A1 (en) 2004-10-14
MXPA05010660A (es) 2005-12-12
AU2004226517B2 (en) 2008-01-24
AU2004226517A1 (en) 2004-10-14
CA2520960A1 (en) 2004-10-14
ZA200507945B (en) 2007-04-25
NO20054370L (no) 2005-10-31
US20060194856A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
ZA200500966B (en) Biphasic composition induced by polydextrose and sucrose
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
SE0301650D0 (sv) Novel compounds
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels
EA200702201A1 (ru) Рофлумиласт для лечения лёгочной гипертензии
SE0300988D0 (sv) New use